Back to CVE records
High 7.8Published Oct 6, 2026

CVE-2026-101258Ghostscript: ghostscript: -dsafer sandbox bypass via type 5 shading oob write and procedure-stream use-after-free

Updated under an hour ago ()

Does this affect you?

It affects Red Hat Enterprise Linux 10. Add what you run to find out whether that includes you.

EPSS puts the chance of exploitation in the next 30 days at 0.18%, higher than 7% of scored CVEs.

A flaw was found in Ghostscript. When Ghostscript renders a crafted PostScript or EPS document, it can bypass the -dSAFER sandbox and execute arbitrary shell commands in the context of the Ghostscript process. The issue chains memory corruption in document parsing with disabling of internal path access controls at runtime. An attacker can deliver the document directly or through formats that delegate rendering to Ghostscript (for example EPS import or print conversion workflows). Successful exploitation can compromise confidentiality, integrity, and availability of data accessible to the process running Ghostscript.

CVSS
7.8 HIGH (v3.1, CNA)CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H
Weakness (CWE)
CWE-787
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
0.18% (percentile 7)
Assigned by
redhat
NVD analysis
Awaiting Analysis
Record last updated
Oct 15, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
from 0:10.02.1-16.el10_2.3 not affected
CNA record

References

  • vendor-advisory, x-refsource-redhat
  • vendor-advisory, x-refsource-redhat
  • vendor-advisory, x-refsource-redhat
  • vdb-entry, x-refsource-redhat
  • issue-tracking, x-refsource-redhat

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.